Kraj: Kanada
Język: angielski
Źródło: Health Canada
IOPROMIDE
BAYER INC
V08AB05
IOPROMIDE
50%
SOLUTION
IOPROMIDE 50%
INTRAVASCULAR
50/200ML
Ethical
ROENTGENOGRAPHY
Active ingredient group (AIG) number: 0125805001; AHFS:
CANCELLED POST MARKET
2019-04-16
ULTRAVIST ® (IOPROMIDE INJECTION) ULTRAVIST ® 300 (IOPROMIDE INJECTION 62% W/V, 300 MG I/ML) ULTRAVIST ® 370 (IOPROMIDE INJECTION 77% W/V, 370 MG I/ML) Nonionic Iodinated Radiographic Contrast Medium For Professional Use Only Bayer Inc. Date of Revision: 2920 Matheson Boulevard East January 22, 2020 Mississauga, Ontario L4W 5R6 Canada http://www.bayer.ca Submission Control No. 234206 ® TM see www.bayer.ca/tm-mc © 2019, Bayer Inc. _ULTRAVIST Product Monograph _ _Page 2 of 60_ ULTRAVIST ® (IOPROMIDE INJECTION) ULTRAVIST ® 300 (IOPROMIDE INJECTION 62% W/V, 300 MG I/ML) ULTRAVIST ® 370 (IOPROMIDE INJECTION 77% W/V, 370 MG I/ML) Nonionic Iodinated Radiographic Contrast Medium For Professional Use Only ACTION AND CLINICAL PHARMACOLOGY ULTRAVIST (iopromide) is a nonionic iodinated, water-soluble, radiographic contrast medium which is available in two stable, ready-to-use solutions of different concentrations. Following intravascular injection, iopromide provides radiographic opacification of the vasculature and extracellular space in the path of flow of the agent, allowing diagnostic assessment of the limbs and internal organs until significant dilution occurs. For example, after intravenous injection, opacification of the renal parenchyma begins within 1 minute. Excretion of the contrast agent becomes apparent in 1 to 3 minutes with optimal contrast in the calyces and collecting system occurring between 5 and 15 minutes. In nephropathic conditions, particularly when excretory capacity has been altered, the excretion rate varies unpredictably and opacification may be delayed for several hours after injection. _ULTRAVIST Product Monograph _ _Page 3 of 60_ The pharmacokinetics of iopromide are similar to those of other ionic and nonionic contrast media. Immediately following intravascular injection, iopromide reaches peak plasma concentrations and is then rapidly distributed throughout the extracellular fluid compartment. It is excreted unchanged by the kidneys mainly by glomerular filtration. About 90% of the inj Przeczytaj cały dokument